MSOT for Assessment of Intestinal Transit Time in Lactose Intolerance Patients
NCT ID: NCT06617364
Last Updated: 2025-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2024-11-11
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Lactose intolerance is caused by a deficiency in the enzyme lactase, which is responsible for breaking down lactose into glucose and galactose. Without this breakdown, lactose is fermented by colon bacteria, leading to symptoms such as bloating and diarrhea. The prevalence of lactose intolerance is increasing, especially among children, and the current diagnostic gold standard is the hydrogen breath test, which, while specific, has limitations in sensitivity.
MSOT could fill this diagnostic gap by non-invasively measuring intestinal transit time and providing a more objective assessment of the condition.
The study will compare MSOT results with H2 breath test outcomes, particularly focusing on patients with varying disease durations and activity levels.
Additionally, participants are offered an optional MRI examination, which can be used to measure intestinal motility. This helps to further quantify the results of the MSOT examination and discover new findings regarding the extent of the disease.
MSOT could improve the sensitivity of lactose intolerance diagnosis, differentiate it from other conditions, and offer insights into disease management over time.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Contrast-enhanced Multispectral Optoacoustic Tomography for Functional Assessment of the Gastrointestinal Transit
NCT05933096
Gastrointestinal Transit Times and Motility in Healthy Volunteers Obtained by Motilis-3D-transit
NCT01635491
Optoacoustic Characterization of Postprandial Intestinal Blood Flow
NCT05160077
Combined Lactulose H2-breath Test With Abdominal Imaging
NCT07145580
Intestinal Permeability and Gastroparesis
NCT04894656
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pediatric patients with suspected lactose intolerance
On the one hand the patients will undergo the hydrogen breath test and on the other their gastrointestinal transit time will be measured using MSOT and ICG contrast agent.
gastrointestinal transit time measurement using MSOT and ICG contrast agent
The subject arrives at the clinic in the morning, fasting according to the preparation instructions from the Childrens Hospital Erlangen for the H2 breath test. Before taking the liquid containing lactose and ICG, the first measurement is performed using MSOT, followed by the H2 breath test. After the liquid to be detected is fully consumed, the second H2 breath test measurement, which only takes a few minutes, is conducted. According to the official guidelines of the Childrens Hospital Erlangen, the hydrogen concentration in the breath is measured at 30-minute intervals. During the 30-minute breaks, further MSOT measurements are carried out, also at 30-minute intervals. Each of these only takes about 10 minutes, they do not interfere with the H2 breath test measurement routine. After the ninth and final H2 breath test measurement a final MSOT examination is conducted. Afterwards participants are offered an optional MRI examination, which can be used to measure intestinal motility.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gastrointestinal transit time measurement using MSOT and ICG contrast agent
The subject arrives at the clinic in the morning, fasting according to the preparation instructions from the Childrens Hospital Erlangen for the H2 breath test. Before taking the liquid containing lactose and ICG, the first measurement is performed using MSOT, followed by the H2 breath test. After the liquid to be detected is fully consumed, the second H2 breath test measurement, which only takes a few minutes, is conducted. According to the official guidelines of the Childrens Hospital Erlangen, the hydrogen concentration in the breath is measured at 30-minute intervals. During the 30-minute breaks, further MSOT measurements are carried out, also at 30-minute intervals. Each of these only takes about 10 minutes, they do not interfere with the H2 breath test measurement routine. After the ninth and final H2 breath test measurement a final MSOT examination is conducted. Afterwards participants are offered an optional MRI examination, which can be used to measure intestinal motility.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent of the subject\'s legal guardian
* Suspicion or diagnosis of lactose intolerance
* Age 6 to 18 years
Exclusion Criteria
* Breastfeeding mothers
* Tattoo in the examination area
* Subcutaneous fat tissue over 3 cm
* Known hypersensitivity to ICG, sodium iodide, or iodine
* Hyperthyroidism, focal or diffuse thyroid autonomy
* Recent treatment for thyroid function assessment involving radioactive iodine (within two weeks before or after the study)
* Impaired renal function
* Use of the following medications: beta-blockers, anticonvulsants, cyclopropane, bisulfite compounds, haloperidol, heroin, meperidine, metamizole, methadone, morphine, nitrofurantoin, opium alkaloids, phenobarbital, phenylbutazone, probenecid, rifamycin, any injection containing sodium bisulfite
* General contraindications for MRI examinations (e.g., electrical implants such as pacemakers or infusion pumps, etc.)
* Severe claustrophobia
6 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Erlangen-Nürnberg Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ferdinand Knieling
PD Dr. med. Dr. rer. biol. hum.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adrian Regensburger, PD Dr. med. Dr. rer. biol. hum
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Erlangen
Erlangen, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MSOT_ICG_LI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.